The global targeted RNA sequencing market size was valued at USD 2.46 billion in 2024. The market is projected to grow from USD 3.05 billion in 2025 to USD 10.94 billion by 2032, exhibiting a CAGR of 24.4% during the forecast period.
Targeted RNA sequencing (RNA-Seq) is a precision molecular biology technique that selectively sequences specific RNA transcripts of interest. This method provides both quantitative gene expression data and qualitative information about transcript variants, making it invaluable for research and clinical applications. The technology primarily employs two approaches: enrichment-based sequencing (which captures broader transcript regions) and amplicon sequencing (which targets specific exons or fusion points).
Get free sample of this report at : https://www.24lifesciences.com/download-sample/2057/targeted-rna-sequencing-market
The market growth is driven by increasing adoption in cancer research, where targeted RNA-Seq enables efficient detection of gene fusions and splice variants. Furthermore, advancements in next-generation sequencing platforms and rising demand for personalized medicine are accelerating adoption. North America currently dominates with 32% market share, followed by Europe at 28%, reflecting strong research infrastructure in these regions. Key players including Thermo Fisher, Illumina, and Roche collectively hold 52% market share, indicating moderate industry consolidation.
Recent Developments and Key Innovations
- Advancements in RNA-Seq Platforms:
Major players such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences have introduced enhanced targeted RNA sequencing kits and platforms offering improved read accuracy, faster throughput, and reduced sequencing costs. - Integration of AI and Bioinformatics:
The integration of artificial intelligence and advanced bioinformatics tools has significantly improved data analysis efficiency, enabling deeper insights into gene expression, alternative splicing, and disease-specific RNA signatures. - Expansion of Clinical Applications:
Targeted RNA sequencing is increasingly being used for oncology, infectious diseases, and rare genetic disorder diagnostics, supporting precision medicine initiatives and biomarker discovery. - Emergence of Single-Cell RNA Sequencing (scRNA-seq):
Recent developments in single-cell RNA sequencing have enabled researchers to explore cell-to-cell variability and heterogeneity, offering more granular transcriptomic insights. - Collaborations and Research Initiatives:
Strategic collaborations between research institutes and biotech companies—such as partnerships between Illumina and Genomics England—are accelerating the development of clinically relevant RNA sequencing panels. - Automation and Workflow Miniaturization:
Automation in library preparation and sequencing workflows is enhancing reproducibility and scalability, enabling higher sample throughput for large-scale studies. - Focus on Long-Read Sequencing:
Companies like Oxford Nanopore Technologies and PacBio are investing in long-read sequencing innovations to overcome limitations of short-read technologies, improving isoform detection and transcript assembly
MARKET DRIVERS
Advancements in Transcriptomics Research to Accelerate Targeted RNA Sequencing Adoption
The global targeted RNA sequencing market is experiencing robust growth driven by increasing applications in transcriptomics research. Recent technological advancements have enabled researchers to analyze specific RNA transcripts with unprecedented precision, particularly in cancer research and rare disease studies. The method’s ability to detect both known and novel fusion transcripts with high sensitivity makes it indispensable for modern genomic studies. With over 60% of research institutions now incorporating RNA sequencing in their workflows, demand for targeted approaches continues to surge, particularly for projects requiring focused analysis of specific gene panels.
Growing Precision Medicine Applications Fuel Market Expansion
Targeted RNA sequencing plays a pivotal role in precision medicine initiatives, particularly in oncology diagnostics and treatment selection. The technology’s ability to quantify gene expression levels and detect splice variants enables clinicians to make more informed therapeutic decisions. In oncology alone, the adoption of RNA-based biomarker panels has grown by over 35% in the past three years, as they provide crucial information about tumor heterogeneity and resistance mechanisms. Pharmaceutical companies are increasingly leveraging these insights to develop more effective targeted therapies, further driving market growth.
➤ For instance, several leading cancer centers have implemented custom targeted RNA panels that can analyze over 1,000 cancer-related transcripts from minimal biopsy samples, enabling more precise treatment stratification.
Furthermore, the integration of artificial intelligence with RNA sequencing data analysis is creating new opportunities for biomarker discovery and clinical decision support systems. This technological synergy is expected to significantly enhance the clinical utility of targeted RNA sequencing in the coming years.
MARKET OPPORTUNITIES
Emerging Applications in Infectious Disease Surveillance Create New Growth Avenues
The recent pandemic has highlighted the potential of targeted RNA sequencing for pathogen surveillance and outbreak monitoring. Public health agencies worldwide are increasingly adopting this technology to track viral variants and study host-pathogen interactions. The ability to simultaneously sequence host and pathogen RNA from clinical samples provides unique insights into disease mechanisms and treatment responses.
Development of Integrated Sample-to-Answer Systems Presents Lucrative Prospects
Several leading companies are developing fully automated targeted RNA sequencing systems that simplify workflow and reduce hands-on time. These integrated solutions combine sample preparation, sequencing, and basic analysis in single platforms, making the technology more accessible to clinical laboratories. The first generation of these systems is already showing promising adoption rates, particularly in hospital settings where workflow efficiency is paramount.
Additionally, the growing interest in liquid biopsy applications is opening new opportunities for targeted RNA sequencing in non-invasive diagnostics. The ability to detect and analyze circulating tumor RNA from blood samples could revolutionize cancer monitoring and enable more frequent treatment response assessments.
List of Key Targeted RNA Sequencing Companies Profiled
Thermo Fisher Scientific Inc. (U.S.)
Illumina, Inc. (U.S.)
Roche Holdings AG (Switzerland)
BGI Group (China)
Eurofins Scientific (Luxembourg)
LabCorp (U.S.)
Berry Genomics (China)
Macrogen (South Korea)
GENEWIZ (U.S.)
The competitive landscape continues to evolve as companies increasingly invest in automation and artificial intelligence integration to improve data analysis capabilities. While large players focus on end-to-end solutions, smaller companies are finding success by specializing in niche applications such as single-cell RNA sequencing or particular disease areas.
Segment Analysis:
By Type
Enrichment Sequencing Leads Due to its High Accuracy in Gene Expression Analysis
The market is segmented based on type into:
Exome Sequencing
Enrichment Sequencing
Subtypes: Transcriptome-wide, Gene Panel-Based, and others
Amplicon Sequencing
Others
By Application
Research Institutes Segment Dominates Owing to Extensive Genomics Studies
The market is segmented based on application into:
Research Institutes
Hospitals & Clinics
Biotechnology Companies
Subtypes: Drug Development, Diagnostics, and others
Diagnostic Laboratories
By Technology
Next-Generation Sequencing Holds Major Share Due to High-Throughput Capabilities
The market is segmented based on technology into:
Next-Generation Sequencing (NGS)
Subtypes: Illumina, Ion Torrent, and others
qPCR
Microarrays
By Disease Area
Oncology Research Drives Market Growth with Rising Genetic Mutation Studies
The market is segmented based on disease area into:
Oncology
Infectious Diseases
Rare Genetic Disorders
Autoimmune Diseases
Others
TARGETED RNA SEQUENCING MARKET TRENDS
Precision Genomics and Therapeutic Applications Drive Market Expansion
The global Targeted RNA Sequencing Market is experiencing robust growth due to increasing demand for precision medicine and oncological research. Valued at $2.46 billion in 2024, the market is projected to grow at a CAGR of 24.4% through 2032, reaching approximately $10.94 billion. This surge is primarily driven by the ability of targeted RNA-Seq to analyze specific transcripts with high accuracy, enabling researchers to study gene expression patterns, splice variants, and novel fusion genes in diseases like cancer. The technique’s cost-effectiveness compared to whole transcriptome sequencing—up to 50% lower in some cases—has further accelerated adoption in academic and clinical settings.
Other Trends
Integration of AI and Automation in RNA-Seq Workflows
Artificial intelligence is transforming targeted RNA sequencing by improving data analysis efficiency and reducing turnaround times. Machine learning algorithms are now capable of identifying subtle expression patterns that correlate with disease progression, enhancing diagnostic accuracy in oncology applications. Automation of library preparation and sequencing processes has reduced human error rates by nearly 30%, while next-generation sequencing platforms now achieve read accuracies exceeding 99.9% for targeted panels. These technological leaps are particularly impactful in therapeutic areas requiring rapid results, such as infectious disease surveillance and rare genetic disorder diagnosis.
Get free sample of this report at : https://www.24lifesciences.com/download-sample/2057/targeted-rna-sequencing-market
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: http://www.24lifesciences.com
Follow us on LinkedIn: http://www.linkedin.com/company/lifesciences24
